| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | Tb4Y |
| Uniprot No | O14604 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-44aa |
| 氨基酸序列 | MSDKPGMAEIEKFDKSKLKKTETQEKNPLSSKETIEQERQAGES |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于Tb4Y(推测为胸腺素β4重组蛋白)的3篇参考文献示例，基于常见相关研究整理：
1. **文献名称**：*"Recombinant Thymosin Beta-4 Promotes Wound Healing in Diabetic Mice"*
**作者**：Huff T. 等
**摘要**：研究证明重组胸腺素β4(Tβ4)通过增强细胞迁移和减少炎症反应，显著加速糖尿病小鼠的皮肤创伤修复，为慢性伤口治疗提供潜在疗法。
2. **文献名称**：*"Expression of Recombinant Human Thymosin β4 in Escherichia coli and Its Biological Activity"*
**作者**：Xu G.J. 等
**摘要**：成功在大肠杆菌中高效表达可溶性重组人Tβ4蛋白，体外实验证实其具有促进血管生成和细胞增殖的活性，为规模化生产奠定基础。
3. **文献名称**：*"Thymosin β4: A Key Factor in Cardiac Protection and Repair"*
**作者**：Goldstein A.L. 等
**摘要**：综述指出重组Tβ4通过调节心肌细胞存活、抗纤维化和促进血管新生，在心肌梗死模型中展现出显著的心脏保护与修复作用。
---
**注意**：若“Tb4Y”为特定重组变体(如酵母表达系统)，建议核实名称准确性。实际文献需通过学术数据库(如PubMed)以准确关键词检索。
**Background of Tb4Y Recombinant Protein**
Tb4Y, a synthetic variant of thymosin beta-4 (Tβ4), is a recombinant protein engineered to mimic the biological functions of its natural counterpart while enhancing stability or activity. Thymosin beta-4. a 43-amino-acid peptide, is a key actin-sequestering protein involved in cell migration, tissue repair, and anti-inflammatory responses. It plays critical roles in wound healing, angiogenesis, and stem cell differentiation by regulating cytoskeletal dynamics and modulating signaling pathways like TGF-β and ILK.
The recombinant Tb4Y protein is typically produced using bacterial or eukaryotic expression systems, such as *E. coli* or yeast, ensuring high purity and scalability. Modifications in the Tb4Y sequence may include amino acid substitutions or fusion tags to improve solubility, prolong half-life, or facilitate targeted delivery. These enhancements aim to overcome limitations of native Tβ4. such as rapid degradation *in vivo* or low bioavailability.
Research on Tb4Y focuses on its therapeutic potential in regenerative medicine, particularly for treating cardiovascular injuries, neurodegenerative diseases, and dermal wounds. Preclinical studies highlight its ability to reduce fibrosis, promote tissue regeneration, and suppress excessive inflammation. Its mechanisms may involve upregulating anti-apoptotic genes, enhancing cell survival under stress, and stimulating extracellular matrix remodeling.
As a research tool, Tb4Y is also used to study actin-mediated cellular processes and disease models linked to cytoskeletal dysfunction. Ongoing efforts aim to optimize its pharmacokinetics and evaluate safety profiles for clinical translation. The development of Tb4Y exemplifies the application of protein engineering to harness natural bioactive molecules for advanced therapeutic strategies.
×
